CytRx

company

About

CytRx is a biopharmaceutical research and development company specializing in oncology.

  • 1 - 10

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$40M
Industries
Biopharma,Biotechnology,Health Diagnostics,Medical
Founded date
Jan 1, 1985
Number Of Employee
1 - 10
Operating Status
Active

CytRx is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. The Company is initiating a Phase 3 pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx is expanding its pipeline of oncology candidates based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. The Company completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib, and is evaluating further development of tamibarotene.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$40M
CytRx has raised a total of $40M in funding over 2 rounds. Their latest funding was raised on Feb 8, 2016 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 8, 2016 Post-IPO Debt $40M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
CytRx is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Post-IPO Debt